Mitchell F. Brin

Q: What Schools Are Affiliated With Mitchell F. Brin

Mitchell F. Brin is affiliated with the following schools: University of California, Irvine, Vanderbilt University

Mitchell F. Brin's AcademicInfluence.com Rankings

Mitchell F. Brin

Medical

#2296

World Rank

#2711

Historical Rank

Neurology

#218

World Rank

#294

Historical Rank

medical Degrees

Mitchell F. Brin

Philosophy

#6691

World Rank

#9772

Historical Rank

Logic

#3819

World Rank

#5031

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Mitchell F. Brin's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Mitchell F. Brin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Mitchell F. Brin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Consensus Statement of the Movement Disorder Society on Tremor (2008) (1999)
A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease (2003) (1457)
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. (1993) (1186)
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein (1997) (994)
Therapeutic uses of botulinum toxin. (1991) (803)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program (2010) (744)
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. (2005) (575)
Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology (1997) (438)
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm (1987) (426)
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. (1999) (417)
Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. (2011) (415)
Idiopathic cervical dystonia: Clinical characteristics (1991) (389)
The DYT1 phenotype and guidelines for diagnostic testing (2000) (358)
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. (2012) (310)
Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study (2000) (307)
Double‐blind, placebo‐controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis (1990) (292)
Human gene for torsion dystonia located on chromosome 9q32-q34 (1989) (249)
Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. (1995) (238)
Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia (1997) (231)
Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia) (1988) (228)
Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled Study (2005) (225)
Idiopathic dystonia among ashkenazi jews: Evidence for autosomal dominant inheritance (1989) (210)
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. (1999) (206)
A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor (2001) (205)
Botulinum Toxin A for Hyperkinetic Facial Lines: Results of a Double-Blind, Placebo-Controlled Study (1994) (203)
Botulinum toxin for the treatment of hyperfunctional lines of the face. (1993) (202)
Criteria for the diagnosis of essential tremor. (2000) (196)
Botulinum toxin: Historical perspective and potential new indications (1997) (195)
Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12‐year experience in more than 900 patients (1998) (189)
Botulinum Toxin Injection for the Treatment of Oromandibular Dystonia (1989) (184)
Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay (2008) (181)
Novel mutation in the TOR1A (DYT1) gene in atypical, early onset dystonia and polymorphisms in dystonia and early onset parkinsonism (2001) (178)
Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains (2014) (172)
Dystonia in Ashkenazi Jews: Clinical characterization of a founder mutation (1994) (169)
Idiopathic torsion dystonia linked to chromosome 8 in two mennonite families (1997) (169)
Laryngeal Dystonia: A Series with Botulinum Toxin Therapy (1991) (165)
Distant effects of local injection of botulinum toxin (1987) (161)
The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. (1997) (160)
Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis (2002) (151)
Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications (2010) (148)
The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. (1999) (146)
Distant effects of locally injected botulinum toxin: A double‐blind study of single fiber EMG changes (1991) (138)
Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32–34 (1990) (138)
Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. (1999) (137)
Electromyographic Findings in Focal Laryngeal Dystonia (Spastic Dysphonia) (1985) (130)
Transgenic mouse model of early-onset DYT1 dystonia. (2005) (129)
Strong allelic association between the torsion dystonia gene (DYT1) andloci on chromosome 9q34 in Ashkenazi Jews. (1992) (126)
Primary lateral sclerosis. A clinical diagnosis reemerges. (1988) (125)
The DYT1 gene on 9q34 is responsible for most cases of early limb-onset idiopathic torsion dystonia in non-Jews. (1994) (124)
Use of Botulinum Toxin for Diagnosis and Management of Cricopharyngeal Achalasia (1997) (123)
Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson's disease. (2004) (120)
Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. (2009) (120)
The role of deep brain stimulation as a surgical treatment for Parkinson's disease. (2000) (118)
Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult‐onset spasticity (1997) (117)
Immunohistochemical localization and distribution of torsinA in normal human and rat brain (2000) (114)
Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies (2016) (113)
Studies of penetrance and anticipation in five autosomal‐dominant restless legs syndrome pedigrees (1999) (112)
TorsinA accumulation in Lewy bodies in sporadic Parkinson’s disease (2000) (110)
Speech dysfunction in early Parkinson's disease (1995) (107)
Distal axonopathy associated with chronic gluten enteropathy (1988) (107)
Treatment of Hyperfunctional Lines of the Face with Botulinum Toxin A (1998) (103)
Use of intrathecal baclofen in the treatment of patients with dystonia. (1996) (103)
Abductor laryngeal dystonia: A series treated with botulinum toxin (1992) (103)
ε‐sarcoglycan mutations found in combination with other dystonia gene mutations (2002) (99)
Intrathecal baclofen for dystonia: Benefits and complications during six years of experience (2000) (99)
Delayed‐onset dystonia due to perinatal or early childhood asphyxia (1991) (98)
Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12‐year experience in more than 900 patients (1998) (97)
Treatment of vaginismus with botulinum toxin injections (1997) (96)
Chorea-acanthocytosis: genetic linkage to chromosome 9q21. (1997) (95)
placebo-controlled phase of the PREEMPT 2 trial OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, (2011) (94)
Treatment of adductor laryngeal breathing dystonia with botulinum toxin type a (1994) (93)
Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle? (2016) (93)
Phenotypic features of myoclonus-dystonia in three kindreds (2002) (91)
Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. (1986) (91)
Segregation analysis of idiopathic torsion dystonia in Ashkenazi Jews suggests autosomal dominant inheritance. (1990) (85)
Botulinum toxin type A products are not interchangeable: a review of the evidence (2014) (82)
Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. (2006) (81)
Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin. (1998) (80)
Adductor laryngeal dystonia (spastic dysphonia): Treatment with local injections of botulinum toxin (Botox) (1989) (79)
TorsinA immunoreactivity in brains of patients with DYT1 and non-DYT1 dystonia (2002) (77)
Pharmacologic treatment of essential tremor. (2000) (75)
Autosomal dominant chorea–acanthocytosis with polyglutamine-containing neuronal inclusions (2002) (71)
Comparison of Therapeutic Efficacies of Type A and F Botulinum Toxins for Blepharospasm (1995) (71)
Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. (2007) (70)
Fine localization of the torsion dystonia gene (DYT1) on human chromosome 9q34: YAC map and linkage disequilibrium. (1997) (69)
A major locus for myoclonus-dystonia maps to chromosome 7q in eight families. (2000) (68)
OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology (2013) (67)
A study of idiopathic torsion dystonia in a non‐Jewish family (1994) (66)
BOTULINUM TOXIN FOR THE TREATMENT OF SPASTICITY IN MULTIPLE SCLEROSIS: New Observations (1993) (66)
Electrophysiologic features of abetalipoproteinemia (1986) (65)
De novo mutations (GAG deletion) in the DYT1 gene in two non-Jewish patients with early-onset dystonia. (1998) (65)
Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review (2020) (64)
Use of botulinum toxin type A in the treatment of cervical dystonia. (2000) (63)
Clinical findings of a myoclonus-dystonia family with two distinct mutations (2002) (62)
Genetic testing for early-onset torsion dystonia (DYT1): introduction of a simple screening method, experiences from testing of a large patient cohort, and ethical aspects. (1999) (61)
Efficacy, Tolerability, and Immunogenicity of OnabotulinumtoxinA in a Randomized, Double-Blind, Placebo-Controlled Trial for Cervical Dystonia (2012) (60)
Movement disorders of the larynx (1992) (60)
Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) (2015) (59)
Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy) (2014) (58)
Perioperative use of botulinum toxin for movement disorder–induced cervical spine disease (1996) (56)
Pregnancy outcomes following exposure to onabotulinumtoxinA† (2015) (55)
Botulinum toxin type A (BOTOX) for treatment of migraine. (2001) (55)
Voice Failure after Tracheoesophageal Puncture: Management with Botulinum Toxin (1995) (54)
Distribution and immunohistochemical characterization of torsinA immunoreactivity in rat brain (2001) (54)
Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin: Review and technical aspects (1992) (54)
Adductor spasmodic dysphonia: standard evaluation of symptoms and severity. (1997) (53)
Epidemiology and Genetics of Essential Tremor (2008) (52)
The gene (DYT1) for early-onset torsion dystonia encodes a novel protein related to the Clp protease/heat shock family. (1998) (51)
Laryngeal botulinum toxin injections for disabling stuttering in adults (1994) (51)
Levodopa neurotoxicity (1998) (51)
Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine (2014) (49)
Parkinsonism associated with Sjögren's syndrome: Three cases and a review of the literature (1999) (49)
Genetic analysis of three patients with an 18p− syndrome and dystonia (1999) (48)
Botulinum toxin injections for lingual dystonia (1991) (46)
Phenotypic spectrum and sex effects in eleven myoclonus‐dystonia families with ε‐sarcoglycan mutations (2008) (46)
Blind loop syndrome, vitamin E malabsorption, and spinocerebellar degeneration (1985) (46)
Development of onabotulinumtoxinA for chronic migraine (2014) (46)
Assessment: Neuropsychological testing of adults Considerations for neurologists (1996) (46)
Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: A 30‐year experience (2018) (45)
Cervical dystonia pathophysiology and treatment options. (2001) (43)
A program for neuropsychological investigation of deep brain stimulation (PNIDBS) in movement disorder patients: development, feasibility, and preliminary data. (2000) (43)
Intrathecal baclofen in the treatment of dystonia. (1998) (42)
Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injection (2017) (41)
Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia (2000) (40)
Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines. (2011) (39)
Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson’s disease (MSPD) (2004) (39)
Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes (2017) (39)
Identification of a highly polymorphic microsatellite VNTR within the argininosuccinate synthetase locus: exclusion of the dystonia gene on 9q32-34 as the cause of dopa-responsive dystonia in a large kindred. (1991) (39)
The effects of intensive speech treatment on intelligibility in Parkinson's disease: A randomised controlled trial (2020) (38)
Exclusion of the DYT1 locus in a non‐Jewish family with early‐onset dystonia (1994) (38)
Oromandibular dystonia: Treatment of 96 patients with botulinum toxin A (1994) (37)
Dyspnea in dystonia. A functional evaluation. (1995) (37)
A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia (2003) (37)
Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia (2014) (37)
Genetic evidence for an association of the TOR1A locus with segmental/focal dystonia (2010) (35)
A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group. (1994) (35)
Distant effects of locally injected botulinum toxin: incidence and course. (1988) (34)
Secondary dystonia and the DYTI gene (1997) (33)
Neurologic disorders and aspiration. (1988) (32)
Dose response with onabotulinumtoxinA for post‐stroke spasticity: A pooled data analysis (2011) (31)
Dystonia in a patient with deletion of 18q (1995) (30)
Neurochemical findings in neuroacanthocytosis (1988) (29)
Speech therapy in Parkinson's disease (2002) (28)
Anticholinergic therapies in the treatment of Parkinson's disease (2002) (28)
BOTULINUM TOXIN FOR TREATMENT OF SPASTICITY IN MULTIPLE SCLEROSIS (1992) (28)
Botulinum Toxin Management of Adductor Spasmodic Dysphonia after Failed Recurrent Laryngeal Nerve Section (2003) (28)
Analysis of the clinical course of non‐Jewish, autosomal dominant torsion dystonia (1986) (28)
Combined use of type A and F botulinum toxins for blepharospasm: A double‐blind controlled trial (1999) (27)
Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders (1994) (27)
OnabotulinumtoxinA Treatment of Mild Glabellar Lines in Repose (2010) (26)
OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females (2019) (25)
Impact of Cervical Dystonia on Work Productivity: An Analysis From a Patient Registry (2015) (25)
Botulinum toxin A: a novel method to remove periorbital wrinkles. (1994) (25)
Movement disorder in reflex sympathetic dystrophy: A case proven to be psychogenic by surveillance video monitoring (1997) (25)
Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE) (2011) (24)
Botulinum toxin type A (BOTOX) for treatment of migraine. (2002) (24)
What is it? case 1, 1996: Rapidly progressive parkinsonism, incontinence, impotency, and levodopa‐induced moaning in a patient with multiple myeloma (1996) (23)
A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine (2020) (23)
Surgical therapies for Parkinson's disease. A physician's perspective. (2001) (23)
Linkage analysis in a family with dominantly inherited torsion dystonia: exclusion of the pro-opiomelanocortin and glutamic acid decarboxylase genes and other chromosomal regions using DNA polymorphisms. (1986) (23)
Basic and clinical aspects of BOTOX. (2009) (22)
The dystonic larynx (1992) (22)
Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats (2019) (21)
Interventional neurology: treatment of neurological conditions with local injection of botulinum toxin. (1991) (20)
Development of future indications for BOTOX. (2009) (20)
A Prospective, Nonrandomized, Open‐Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis (2015) (19)
Amantadine and other antiglutamate agents (2002) (19)
Corticospinal excitability accompanying ballistic wrist movements in primary dystonia (2004) (19)
Cervical Dystonia (2012) (19)
Relationship between Dose of Vitamin E Administered and Blood Level a (1989) (18)
Treatment of Torticollis with Injections of Botulinum Toxin (1987) (18)
Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study (2019) (18)
Inheritance of idiopathic torsion dystonia among Ashkenazi Jews. (1988) (18)
Phenylalanine loading as a diagnostic test for DRD: interpreting the utility of the test. (2004) (18)
Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia (2002) (18)
Treatment of depression in idiopathic Parkinson's disease (2002) (17)
Neuropsychiatric aspects of adult-onset Tay-Sachs disease: two case reports with several new findings. (1993) (17)
The role of the DYT1 gene in secondary dystonia. (1998) (16)
Biotin-responsive encephalopathy with myoclonus, ataxia, and seizures. (1986) (16)
Neck Pain and Cervical Dystonia: Treatment Outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy) (2016) (15)
Botulinum toxin: dangerous terminology errors. (1993) (15)
Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons (2020) (14)
Cervical dystonia (torticollis) (1999) (14)
Assessment: Dermatomal somatosensory evoked potentials (1997) (14)
Drugs to treat dementia and psychosis (2002) (14)
Transgenic mouse model of early-onset DYT 1 dystonia (2004) (13)
Disorders with Excessive Muscle Contraction: Candidates for Treatment with Intramuscular Botulinum Toxin (“Botox”) (1993) (13)
Repeated OnabotulinumtoxinA Treatment of Glabellar Lines at Rest Over Three Treatment Cycles (2016) (13)
MAO‐B inhibitors for the treatment of Parkinson's disease (2002) (13)
Assessment: DTP vaccination: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (1992) (12)
Molecular genetics of an autosomal dominant form of torsion dystonia. (1988) (11)
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A–responsive cervical dystonia (1999) (11)
Novel Native and Engineered Botulinum Neurotoxins. (2020) (11)
Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study (2019) (10)
Drugs to treat autonomic dysfunction in Parkinson's disease (2002) (9)
Cerebral Involvement in McLeod Syndrome: The First Autopsy Revisited (2008) (9)
Acoustic Assessment of Vocal Function (2009) (9)
Other noncosmetic uses of BOTOX. (2002) (9)
Severe generalized dystonia due to primary putaminal degeneration: Case report and review of the literature (2002) (8)
Surgical treatment for Parkinson's disease: Deep brain surgery (2002) (8)
Botulinum toxin for the treatment of oromandibulolingual omd dystonia (1989) (7)
Drug-diet interactions. (1979) (6)
ESSENTIAL TREMOR. AUTHOR'S REPLY (1992) (6)
The development of toxin neutralising antibodies with botulinum toxin type A (BoNTA) treatment (2005) (6)
DA agonists ‐ Ergot derivaties: Cabergoline (2002) (6)
Cerebellar ataxia, dystonia, and tremor within a family: Variable phenotypes of a single genetic disorder? (2004) (6)
DA agonists ‐ Non‐Ergot derivaties: Ropinirole (2002) (6)
Surgical treatment for Parkinson's disease: Neural transplantation (2002) (6)
Psychosocial counseling in Parkinson's disease (2002) (6)
Design and Rationale of a Phase 2 Study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of Post-Operative Atrial Fibrillation - The NOVA Study. (2021) (6)
Phase 3 efficacy and safety study of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity (2013) (6)
Surgical Management of Airway Dysfunction in Parkinson's Disease Compared with Parkinson-Plus Syndromes (2013) (6)
Physical and occupational therapy in Parkinson's disease (2002) (5)
Multicentre, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. (2013) (5)
Atogepant – an orally-administered CGRP antagonist – attenuates activation of meningeal nociceptors by CSD (2022) (5)
Orofaciomandibular and lingual dystonia (Meige syndrome): Botulinum toxin treatment (1995) (5)
Laryngeal Sensory Receptors (2009) (5)
Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines (2021) (5)
OnabotulinumtoxinA for Treatment of Chronic Migraine: 75% Responder Analysis Results from the Double-Blind, Randomized, Placebo-Controlled Phase of the PREEMPT Clinical Program (P03.227) (2012) (4)
DA agonists ‐ Non‐Ergot derivaties: Apomorphine (2002) (4)
OnabotulinumtoxinA for Treatment of Chronic Migraine: A Response (2011) (4)
Negative dystonia of the palate: A novel entity and diagnostic consideration in hypernasal speech (2015) (4)
OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays (2020) (4)
OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phase of the PREEMPT clinical program (2013) (4)
Poster 48 : Toxin Neutralizing Antibody Formation With Botulinum Toxin Type A Treatment in Neuromuscular Disorders (2005) (3)
Management of hemifacial spasm and facial synkinesis with local injections of botulinum toxin (2004) (3)
DA agonists ‐ Ergot derivaties: Lisuride (2002) (3)
Guidance for the diagnosis and treatment of hypolipidemia disorders. (2022) (3)
PND11 Cost of Cervical Dystonia in the United States (2012) (3)
Pregnancy outcomes following exposure to onabotulinumtoxinA update: 29 years of safety observation (2021) (3)
Fusion of Golgi‐derived vesicles mediated by SNAP‐25 is essential for sympathetic neuron outgrowth but relatively insensitive to botulinum neurotoxins in vitro (2014) (3)
Interventional neurology: treatment of neurological conditions with local injection of botulinum toxin. (1991) (3)
Torsina Immunoreactivity in Normal and Dyti Brain (2002) (3)
Botulinum toxin in the clinical management of cervical dystonia (2000) (2)
Stroboscopic Examination of the Normal Larynx (2009) (2)
OnabotulinumtoxinA affects cortical recovery period but not occurrence or propagation of cortical spreading depression in rats with compromised blood–brain barrier (2021) (2)
Autosomal-Dominant Chorea-Acanthocytosis: Report of a Family and Neuropathology (2004) (2)
Autosomal Dominant Dystonia in a Large North American Family: Clinical Features (1987) (2)
Electromyography of Laryngeal and Pharyngeal Muscles (2009) (2)
Efficacy and safety of onabotulinumtoxinA with standardized occupational therapy for treatment of pediatric upper limb spasticity: Phase III placebo-controlled randomized trial (2021) (2)
Peripheral Laryngeal Motor Innervation (2009) (2)
Essential tremor (1992) (2)
Low rate of neutralising antibody formation to botulinum toxin type A in the course of treatment of primary axillary hyperhidrosis (2005) (2)
OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT (2013) (2)
Safety of OnabotulinumtoxinA with Concomitant Antithrombotic Therapy in Patients with Muscle Spasticity: A Retrospective Pooled Analysis of Randomized Double-Blind Studies (2020) (2)
OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patients (2021) (2)
International Conference on Botulinum Toxin: Basic Science and Clinical Therapeutics. Munich, Germany, June 14-16, 1995. Abstracts. (1995) (2)
Botulinum toxin in the management of adductor and abductor spasmodic dysphonia (1993) (2)
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. (1988) (2)
Neutralizing antibody conversion with onabotulinumtoxinA from global studies across multiple indications in nearly 30,000 patient records: A meta-analysis (2021) (1)
CLINICOPATHOLOGIC STUDY OF A CASE OF DYSTONIA WITH PUTAMENAL DEGENERATION OF UNKNOWN ETIOLOGY (1999) (1)
Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache (2022) (1)
Inheritance of Primary Torsion Dystonia Among Ashkenazi Jews (1987) (1)
Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: Statistical meta-analysis of pooled data from global registration studies of treatment of crow’s feet lines and glabellar lines in more than 3900 participants (2016) (1)
Erratum to: OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology (2014) (1)
Abstracts from the ASENT 2008 Annual Meeting March 6–8, 2008 (2008) (1)
Letter to the editor: Botulinum type A treatment: no evidence of increased risk of seizures in juvenile cerebral palsy (2010) (1)
AUTHOR RESPONSE (2011) (1)
DA agonists ‐ Non‐Ergot derivaties: Pramipexole (2002) (1)
DA agonists ‐ Ergot derivaties: Dihydroergocryptine (DHEC) (2002) (1)
Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA (2020) (1)
Clinically meaningful differences of the Ashworth Scale in patients with chronic post-stroke upper limb spasticity treated with botulinum neurotoxin type A (botox®) (2008) (1)
Flexible Endoscopic Evaluation of Swallowing with Sensory Testing (FEESST) (2009) (1)
DA agonists ‐ Non‐Ergot derivaties: Piribedil (2002) (1)
Botulax displays lower enzymatic activity when compared to onabotulinumtoxinA in a light chain activity assay (2021) (1)
Linkage studies in families with dystonia: linkage analysis as a tool to locate and characterize the gene(s) for dystonia. (1988) (1)
Physical Examination of the Larynx and Videolaryngoscopy (2009) (1)
Efficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: A randomized, placebo-controlled, phase III clinical trial (2021) (1)
Neurologic Disorders of the Larynx: E-Book (2015) (1)
Drisapersen treatment for Duchenne muscular dystrophy: results of a 96-week follow-up of an open-label extension study following two placebo-controlled trials (2014) (1)
Speech Treatment for Neurologic Disorders (2009) (1)
Botulinum neurotoxin type A–Cleaved SNAP25 is confined to primary motor neurons and expressed on the plasma membrane following intramuscular toxin injection (2016) (1)
Differences in botulinum toxins: Time to end the confusion (2009) (1)
Extracranial Injections of OnabotulinumtoxinA in Combination with Intravenous Injection of Atogepant Attenuates Activation and Sensitization of HT and WDR Neurons by CSD (4287) (2020) (1)
[Cerebral metastases of malignant germinal tumors of the testis]. (1982) (1)
Light microscopic studies in DYTI human and electron microscopic studies in non-human primate brain (2002) (1)
34952 Efficacy and safety of 2 doses of onabotulinumtoxin A for the treatment of masseter muscle prominence: 6-month results from a randomized, phase 2b placebo-controlled study (2022) (0)
Medications and procedures to treat headache (2005) (0)
Treating major depressive disorder with onabotulinumtoxinA: Safety and efficacy 24 weeks following a single injection session (2018) (0)
CNS volume 1 issue 2 Cover and Front matter (1996) (0)
Poster Degeneration and system diseasesClinical neurophysiology of abetalipoproteinemia: Functional consequences of vitamin E deficiency (1985) (0)
Cervical Dystonia Patient Registry for Observation of onaBotulinumtoxinA Efficacy (CD PROBE): Interim results of physician- and patient-reported outcomes (2013) (0)
Physician and Patients in Managing Parkinson's Disease (2000) (0)
OnabotulinumtoxinA for Treatment of Masseter Muscle Prominence: Secondary Results From a Phase 2, Dose-Escalation Study (2022) (0)
Parkinson's disease slide library (1996) (0)
Modulation of amygdala activity for emotional faces due to botulinum toxin type A injections that prevent frowning (2023) (0)
Effect of OnabotulinumtoxinA on Pain in Patients with Cervical Dystonia: Results from CD PROBE (P4.327) (2015) (0)
Management of Spasmodic Dysphonia with Botulinum Toxin (1995) (0)
Treatment of migraine headaches with botulinum toxin A (1999) (0)
35. Pregnancy outcomes following exposure to onabotulinumtoxinA (2015) (0)
Poster 40 Cervical Dystonia Patient Registry for Observation of Botox Efficacy (CD PROBE): Interim Results of Pain‐related Outcomes (2011) (0)
Dystonia clinical research center tissue resource facility: investigations on collected tissue. (1988) (0)
Essential tremor. (1992) (0)
Poster 43: Passive and Active Functional Tasks: Main Reasons for Treatment (or Referral for Treatment) of Upper-Limb Spasticity in Poststroke Patients Among Neurologists, Physiatrists, and Primary Care Physicians (2007) (0)
PS-56-6 Clinical trial of blepharospasm with mixture of types F and A botulinum toxins (1995) (0)
Poster 89 Severity of Cervical Dystonia: Baseline Characteristics from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) (2012) (0)
Cervical dystonia patient registry for observation of onabotulinum /INS;toxin /INS;A efficacy (CD Probe): Pain at baseline (2013) (0)
Dopamine beta-hydroxylase gene excluded in four subtypes of hereditary dystonia (1991) (0)
Safety of onabotulinumtoxina treatment with concomitant antithrombotic therapy in patients with poststroke spasticity: A pooled analysis of randomized, double-blind studies (2016) (0)
Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle (P4.123) (2018) (0)
MYOCLONUS (1996) (0)
Treatment of neuroblastoma (1972) (0)
Pregnancy Outcomes in Patients Exposed to OnabotulinumtoxinA Treatment: A Cumulative 29-Year Safety Update. (2023) (0)
Central Laryngeal Motor Innervation (2009) (0)
Medicaments and methods for treatment of headache (2005) (0)
Clinical Relevance of Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study (P3.016) (2016) (0)
Discussion: Oromandibular dystonia treated with botulinum toxin: Report of case (1995) (0)
Future indications for botulinum toxin (BoNT) (2008) (0)
Evaluation and management of swallowing and voice disorders (1999) (0)
Use of brimonidine to prevent and reduce the severity of stress related conditions (2004) (0)
High Frequency Stimulation of the Subthalamic Nucleus as a Treatment for Parkinson's Disease: A 12 Month Follow-up Study (1999) (0)
Efficacy and Safety of 2 Doses of OnabotulinumtoxinA for the Treatment of Masseter Muscle Prominence: 6-Month Results From a Randomized, Phase 2b Placebo-Controlled Study (2022) (0)
Treatment Outcomes in Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) (P7.069) (2014) (0)
Reply: "Abbreviations for device names: a proposed methodology with specific examples"—Dermatol Surg 2013;1-3. (2014) (0)
A method for treating mammary gland disorders (2003) (0)
DA agonists ‐ Overview (2002) (0)
Poster 507 Evaluation of Pain Relief in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) (2014) (0)
Drugs to treat gastrointestinal motility problems (2002) (0)
DA agonists ‐ Ergot derivaties: Bromocriptine (2002) (0)
Principles of molecular genetics/Dystonia (1992) (0)
Preclinical Assessment of OnabotulinumtoxinA for the Treatment of Mild Traumatic Brain Injury–Related Acute and Persistent Cephalic Allodynia (2022) (0)
Poster 135 Effectiveness and Safety in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) (2014) (0)
OnabotulinumtoxinA is well tolerated in chronic migraine patients taking oral preventive medications: Long-term compel analysis by treatment cycle (2018) (0)
The Impact of Cervical Dystonia on Work Productivity: An Analysis from the CD Patient Registry for the Observation of OnabotulinumtoxinA Efficacy (CD PROBE) (P4.324) (2015) (0)
Masseter Prominence Reduction, Treatment Satisfaction, and Self-Perceived Lower Face Appearance After OnabotulinumtoxinA: Results From a Randomized, Controlled, Phase 2b Trial (2022) (0)
Comprar Neurologic disorders of the larynx | Mitchell F. Brin | 9781588904980 | Thieme (2009) (0)
Safety and efficacy of onabotulinumtoxinA for treatment of masseter muscle hypertrophy: Results from a Phase 2 dose-escalation study (2018) (0)
Poster 251 Treatment Outcomes Following OnabotulinumtoxinA in Patients with Cervical Dystonia Naive to Botulinum Toxin Treatment (2015) (0)
Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Treatment Patterns and Subject Disposition (P7.062) (2014) (0)
Laryngeal Dysfunction in Sleep (2009) (0)
154. Evaluation of pain relief in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) (2015) (0)
A method for the treatment of colorectal cancer with botulinum neurotoxin (2005) (0)
Long-distance spread of botulinum neurotoxin type A in mice persists after peripheral nerve axotomy (2018) (0)
Poster 102: CD‐PROBE (Cervical Dystonia Patient Registry for Observation of Botox Efficacy)— A Multicenter, Observational Study of OnabotulinumtoxinA Injections in Cervical Dystonia (CD) Patients—Baseline Data and Interim Patient Reported Outcome (2010) (0)
Safety and Efficacy of OnabotulinumtoxinA for Treatment of Masseter Muscle Hypertrophy: Results from a Phase 2 Study (2022) (0)
Drugs to treat urinary frequency, urgency, and/or urge incontinence (2002) (0)
Gluten enteropathy causes distal axonopathy with normal vitamin e levels (1986) (0)
• Neurolaryngology Subcommittee: Head and Neck Manifestations of Movement Disorders (With Spanish translation) (1997) (0)
Huntington's disease introduction to diagnosis, genetics, and management (slide library) (1996) (0)
Preface (0)
Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Study Design of a Prospective Observational Registry (2011) (0)
Pulmonary Function Evaluation (2009) (0)
Severity of Cervical Dystonia: Baseline Characteristics from the Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD-PROBE) (P01.231) (2012) (0)
36. Dual mechanistic effects of onabotulinumtoxinA (onabotA) on efferent and afferent neurons (2015) (0)
Abstracts from the ASENT 2007 Annual Meeting March 5–8, 2007 (2007) (0)
Botulinum Toxin-Reply (1995) (0)
PR_033: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Multicenter Study Evaluating the Effect of Botulinum Toxin Type A Treatment on Pulmonary Function in Patients With Poststroke Focal Spasticity (2006) (0)
Treatment of Spasticity with Botulinum Toxin-A Injections (1993) (0)
50. Treatment patterns and patient disposition in the cervical dystonia patient registry for observation of onabotulinumtoxin A efficacy (CD PROBE) (2015) (0)
Current understanding of onabotulinumtoxinA mechanism of action in migraine prophylaxis (2016) (0)
Use of brimonidine to prevent and reduce the severity of conditions associated with stress (2004) (0)
OnabotulinumtoxinA effects on trigeminal nociceptors (2023) (0)
drugs and methods to treat headache (2005) (0)
Poster 320: Passive and Active Functional Tasks Are the Main Reasons for Treatment of Upper-Limb Spasticity in Poststroke Patients Among Neurologists, Physiatrists, and Primary Care Physicians (2007) (0)
Poster 273 Validity and Reliability of the Pictorial Spasmodic Torticollis Rating Scale (2011) (0)
Anatomy of the Larynx (2009) (0)
A cell-penetrating peptide (CPP) did not decrease 150-kDa BoNT/A toxin adsorption to surfaces or increase toxin potency or duration in a prototype formulation (2021) (0)
Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Baseline Demographic and Clinical Characteristics (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Mitchell F. Brin?

Mitchell F. Brin is affiliated with the following schools:

Mitchell F. Brin's Academic­Influence.com Rankings

Mitchell F. Brin's Degrees

Why Is Mitchell F. Brin Influential?

Mitchell F. Brin's Published Works

Published Works

What Schools Are Affiliated With Mitchell F. Brin?

Mitchell F. Brin's AcademicInfluence.com Rankings